USPTO serial 99187637
OPUS
Reviewed by CopyMark Law Group
Status 654
- Filing date
- Status date
- Registration date
- —
- Examiner
- DUBRAY, KATHERINE M
- Law office
- TMO LAW OFFICE 118
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with OPUS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Michael W. Schroeder
Michael W. Schroeder REYES & SCHROEDER ASSOCIATES, P.C.555 Anton Blvd. STE #150Costa Mesa, CA 92626United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Product design and development in the field of lipid nanoparticle (LNP) drug delivery systems for pharmaceutical and therapeutic applications; Product design and development in the field of lipid nanoparticle (LNP) compositions for the delivery of nucleic acid-based therapeutics, including mRNA, siRNA, and DNA; Design and development of software and hardware for optimization and customization of lipid nanoparticle (LNP) drug delivery systems for pharmaceutical and therapeutic applications; Research and development of technology in the field of artificial intelligence-based software tools for lipid discovery, pharmaceutical formulation, and delivery optimization; Providing temporary use of non-downloadable cloud-based software for designing, modeling, and deploying therapeutic delivery systems; Medical and scientific research in the field of lipid nanoparticle (LNP) drug delivery systems for pharmaceutical and therapeutic applications and lipid nanoparticle (LNP) compositions for the delivery of nucleic acid-based therapeutics; Research and development in the field of lipid nanoparticle (LNP) drug delivery systems for pharmaceutical and therapeutic applications and lipid nanoparticle (LNP) compositions for the delivery of nucleic acid-based therapeutics; Technology consultation and research in the field of lipid nanoparticle (LNP) drug delivery systems for pharmaceutical and therapeutic applications and lipid nanoparticle (LNP) compositions for the delivery of nucleic acid-based therapeutics | ACTIVE | Dec 29, 2023 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 25, 2026 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Apr 27, 2026 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Apr 24, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 3, 2025 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Oct 3, 2025 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Oct 3, 2025 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Sep 29, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| May 15, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 15, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 15, 2025 | NWAP | NEW APPLICATION ENTERED | — |